# Alcresta Therapeutics

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/alcresta-therapeutics

- Industry: Biotechnology
- Headquarters: Waltham, US
- Website: www.alcresta.com
- Total disclosed funding: $66M
- Latest round: Series C (Mar 22, 2016)
- Investors on record: 5

## About

Founded in 2011 by Robert Gallotto and Shaheda Ahmed and based in Massachusetts, US, Alcresta Therapeutics, Inc. operates as a developer of innovative enzyme-based nutritional products that improve patient health and manage gastrointestinal disorders and rare diseases. In January 2019, Alcresta Therapeutics, Inc. raised USD 5 million in Series D funding from various investors.

The firm offers products for treating fat malabsorption due to conditions like cystic fibrosis, short bowel syndrome, pancreatitis, and other rare diseases. Their lead product, RELiZORB®, uses patented iLipase® technology to break down fats in enteral feeding formulas, facilitating easier absorption of essential fatty acids. RELiZORB is suitable for pediatric and adult patients and can be used in various care settings. Alcresta also offers additional enzyme therapies for conditions like neonatal pancreatic immaturity.

## Funding rounds

- Series C, Mar 22, 2016, $51M — Frazier Healthcare Partners, Bessemer Venture Partners, Third Rock Ventures, Athyrium Capital Management
- Series B, Jul 12, 2013, $5M — Frazier Healthcare Partners, Bessemer Venture Partners, Third Rock Ventures
- Series A, Sep 9, 2011, $10M — Frazier Technology Ventures, Bessemer Venture Partners, Third Rock Ventures

## Investors

- Frazier Technology Ventures (https://capitalatlas.ai/funds/frazier-technology-ventures) — Series A
- Bessemer Venture Partners (https://capitalatlas.ai/funds/bessemer-venture-partners) — Series A, Series B, Series C
- Third Rock Ventures (https://capitalatlas.ai/funds/third-rock-ventures) — Series A, Series B, Series C
- Frazier Healthcare Partners (https://capitalatlas.ai/funds/frazier-healthcare-partners) — Series B, Series C
- Athyrium Capital Management (https://capitalatlas.ai/funds/athyrium-capital-management) — Series C